Ischemic heart disease
Conditions
Interventions
None listed
Sponsors
Tokorozawa Heart Center
1) The Jikei University School of Medicine, the Department of Laboratory Medicine. 2) National Defense Medical Collage, the Division of Anti-aging, Department of Internal Medicine.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with ischemic heart disease who have significant stenotic lesions on coronary arteries. 2) Patients with heart disease without ischemic heart disease. 3) Healthy volunteers without heart disease. 4) Patients who gave written informed consent
Exclusion criteria
Exclusion criteria: 1) Less than 20 years old, 85 years old or older. 2) Acute coronary syndrome 3) End-stage renal disease (eGFR<30 ml/min) including patients under hemodialysis 4) Type1 diabetes mellitus 5) Subjects who are pregnant or possible to be pregnant 6) Shock 7) Subjects who are planned to have surgical operation or endoscopic therapy in 3 months which needs to stop antiplatelet therapy 8) Subjects whose doctor in charge do not agree to join the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic insulin resistance measured using the fasting 13C-glucose breath test; 13C excretion rate at 2 hours. | — |
Secondary
| Measure | Time frame |
|---|---|
| Insulin resistance calculated using HOMA-IR, High density lipoprotein(HDL) function, the relationship between 13C excretion rate and HDL function, and Blood analyses including Hemoglobin A1c levels, Plasma glucose levels, Immunoreactive insulin levels, Lipid profile, Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), etc. | — |
Countries
Japan
Contacts
Public ContactHirotaka Ezaki
Tokorozawa Heart Center Department of Cardiology
Outcome results
None listed